Research strategies of small molecules as chemotherapeutics to overcome multiple myeloma resistance.
Eur J Med Chem
; 271: 116435, 2024 May 05.
Article
en En
| MEDLINE
| ID: mdl-38648728
ABSTRACT
Multiple myeloma (MM), a cancer of plasma cells, is the second most common hematological malignancy which is characterized by aberrant plasma cells infiltration in the bone marrow and complex heterogeneous cytogenetic abnormalities. Over the past two decades, novel treatment strategies such as proteasome inhibitors, immunomodulators, and monoclonal antibodies have significantly improved the relative survival rate of MM patients. However, the development of drug resistance results in the majority of MM patients suffering from relapse, limited treatment options and uncontrolled disease progression after relapse. There are urgent needs to develop and explore novel MM treatment strategies to overcome drug resistance and improve efficacy. Here, we review the recent small molecule therapeutic strategies for MM, and introduce potential new targets and corresponding modulators in detail. In addition, this paper also summarizes the progress of multi-target inhibitor therapy and protein degradation technology in the treatment of MM.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Asunto principal:
Resistencia a Antineoplásicos
/
Bibliotecas de Moléculas Pequeñas
/
Mieloma Múltiple
/
Antineoplásicos
Límite:
Humans
Idioma:
En
Revista:
Eur J Med Chem
Año:
2024
Tipo del documento:
Article
País de afiliación:
China